| H I STOR Y OF V OXE LOT OR ( PR E VI OU SL Y G BT4 40 )
Voxelotor, a first-in-class drug, is currently being studied for the treatment of sickle cell disease in the United States and Europe that has received Breakthrough Therapy Designation (BTD) by the Food and Drug Administration (FDA) and the European Medicines Agency Priority Medicines (PRIME) designation. As of December 2017, there are three published manuscripts on preclinical data regarding voxelotor.
One describes discovery of the potent allosteric effector of HbS that has a high affinity for hemoglobin, allowing for therapeutic concentrations to be achieved in the erythrocyte with low serum concentrations. 1 A second reports voxelotor prevents sickling of sickle cell trait red blood. 2 Finally, a third that shows in the HbSS Townes knock-in sickle mice voxelotor extends the half-life of erythrocytes, reduces reticulocyte counts, and prevents ex vivo sickling. 3 To date, three clinical trials evaluating voxelotor in individuals with sickle cell disease are either actively recruiting participants or have recently closed to accrual.
The phase I randomized, placebo-controlled, double-blind, single and multiple ascending dose study of the tolerability and pharmacokinetics of GBT440 in healthy subjects and patients with SCD (GBT440-001; NCT02285088) is actively following participants but is closed to enroll- Concern: ". . .it seems uncertain whether the 30% modification by GBT440 would actually be protective for HbS polymerization under in vivo conditions."
The kinetics of deoxy-sickle hemoglobin (deoxy-HbS) polymerization are unusual. Prior to polymerization, there is a delay period (inversely proportional to the 30th power to the deoxy-HbS concentration)
followed by rapid progression of polymer formation. 4 (Figure 1) . 3 The Hebbel model assumed a left shift of the p50 to 18 mm Hg for 30% voxelotor-HbS, 5 however, the p50 at 1000 mg per day is more modest than this at 28 mm Hg with 27% modification. 6, 7 In adults with SCD who received 500 mg (n 5 10) or 700 mg of voxelotor for 28 days, irreversibly sickled cells were reduced, and five individuals continued 700 mg for 90 days and had a sustained reduction in irreversibly sickled cells and irreversibly sickled cells present at 28 days was sustained ( Figure 2 ). These concerns are based on the idea of "Functional Oxygen Content" (FOC), where the FOC is what remains of hemoglobin's total oxygen content after the contribution from an extreme-affinity component is subtracted out. 5 The assumption is that the voxelotor-HbS complex (the therapeutic goal for voxelotor is to modify 20%-30% of HbS) with increased affinity for oxygen decreases (or eliminates) its ability to deliver oxygen to peripheral tissues in the setting of low capillary pO 2 .
In the setting of acute hypoxia, serum erythropoietin (EPO) levels begin to rise within hours and peak around day #3, and this rise in EPO is closely followed by a wave of reticulocytosis beginning on day #2 of hypoxia. 10 In children with SCD, after 16 weeks of 900 mg of voxelotor, the median (IQR) change in hemoglobin compared to baseline was 11.1 g/dL (0.2-1.6 g/dL), and 55% (n 5 6/11) of children had an increase of greater than 1 g/dL. 8 A similar magnitude in the rise of hemoglobin was observed in adults. 10 As Hebbel and Hedlund explain, this magnitude of rise in hemoglobin would be insufficient to mitigate a functional oxygen delivery loss of the 20%-30% of voxelotor-Hb. The hematologic response following initial exposure to voxelotor is provided in Figure 3 . After four days of receiving 500 mg (n 5 10), adults with SCD have stable to slightly lower EPO levels compared to baseline, no change in reticulocyte counts, and increases in hemoglobin values. 11 After 28 days of voxelotor, higher hemoglobin levels and lower reticulocyte percentages compared to baseline are observed in the setting of stable to slightly lower EPO levels 11 and this relationship persists for up to 90 days with exposure to voxelotor. Concern: A rising hemoglobin in response to GBT440 may reflect successful inhibition of polymerization, but this may need not be the case. Indeed, an argument can be made that the drug effect would tend to favor inhibition of the polymerization-independent pathway to sickle RBC destruction previously described that supposedly accounts for two-thirds of hemolysis.
Both adults 1, 8 and children 8 and children treated with voxelotor see reductions in hemolysis with lower levels of unconjugated bilirubin, lactate dehydrogenase, and reticulocytes. The initial drop in bilirubin occurs as early as day #4 after exposure to voxelotor, which corresponds to when a rise in hemoglobin is observed and the reticulocyte count has not begun to decline. 
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| C ONC LUSI ON
Hebbel and Hedlund should be commended for their expert commentary that is a thoughtful, well-crafted, and detailed hypothetical and theoretical model. Indeed, this thought experiment should be performed for all upcoming agents in this new therapeutic class. I suspect that the balance of oxygen-affinity to combat polymerization versus oxygen-delivery to peripheral tissues will be different for each compound. Nevertheless, the available preliminary preclinical and clinical data for voxelotor cannot be explained by the theoretical Hebbel and
Hedlund model and suggests that Eaton and Bunn were correct when they cautioned the physiology of oxygen delivery to peripheral tissues is too complicated to be predicted based on biophysical studies with regards to oxygen affinity-shifting agents. 12 The preliminary data for voxelotor is promising. I eagerly await data from the definitive trials. I remain hopefully optimistic.
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